Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review

Abstract

Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.

Role of the high mobility group box 1 signalling axes via the receptor for advanced glycation end‐products and toll‐like receptor‐4 in the immunopathology of oral lichen planus: a potential drug target?

“… found that HMGB1 polymorphism could be utilized as an indicator of oral cancer progression and could be associated with an increased incidence of oral cancer in patients with OLP. In this context, HMGB1 is induced in many head and neck cancers, where it is correlated with nodal metastasis and poor prognosis . High mobility group box 1 was also found to be upregulated in several systemic disorders, such as lupus erythematosus, diabetes, and rheumatoid arthritis .…”

Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome

“…CRP monitoring is inexpensive, and CRP is currently assessed as a routinely measured marker for TET detection [ 14 ]. Each of the above-mentioned molecules is reportedly linked to inflammation and malignancies [ 15 – 17 ], with inflammatory responses playing crucial roles in various stages of tumor development, including tumor initiation, progression, and metastasis [ 18 – 21 ]. Peripheral blood-derived inflammation-based markers, such as CRP, Fibrinogen, the neutrophil-to-lymphocyte ratio (NLR), and the platelet-to-lymphocyte ratio (PLR) have been widely investigated and identified as prognostic markers in various solid tumors [ 22 – 25 ].…”

Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review

“…The HMGB1-RAGE signaling axis has been implicated in numerous malignancies, including head and neck cancer (16,22). While HMGB1 signaling through TLRs is important in cancer immunobiology, the role of TLRs has already been reviewed (23).…”